CN104714036B - The preparation method of Antithrombin III determination of activity test kit - Google Patents

The preparation method of Antithrombin III determination of activity test kit Download PDF

Info

Publication number
CN104714036B
CN104714036B CN201510151571.XA CN201510151571A CN104714036B CN 104714036 B CN104714036 B CN 104714036B CN 201510151571 A CN201510151571 A CN 201510151571A CN 104714036 B CN104714036 B CN 104714036B
Authority
CN
China
Prior art keywords
reagent
freeze
drying
atiii
redissolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510151571.XA
Other languages
Chinese (zh)
Other versions
CN104714036A (en
Inventor
肖薇
林方昭
谢兆林
杨显福
孙小成
肖玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Union Biotechnology Co ltd
Institute of Hematology and Blood Diseases Hospital of CAMS and PUMC
Original Assignee
Chengdu Union Biotechnology Co ltd
Institute of Hematology and Blood Diseases Hospital of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Union Biotechnology Co ltd, Institute of Hematology and Blood Diseases Hospital of CAMS and PUMC filed Critical Chengdu Union Biotechnology Co ltd
Priority to CN201510151571.XA priority Critical patent/CN104714036B/en
Publication of CN104714036A publication Critical patent/CN104714036A/en
Application granted granted Critical
Publication of CN104714036B publication Critical patent/CN104714036B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121Serpins
    • G01N2333/8128Antithrombin III

Abstract

The present invention relates to a kind of clinical detection reagent preparation method, it is specially the preparation method of Antithrombin III determination of activity test kit, Tris-HCl dissolves zymoplasm lyophilized powder and heparin sodium makes S1 reagent, being dissolved by zymoplasm chromophoric substrate S-2238 or Sar-Pro-Arg-P-nitroanilide Tris-HCl and make S2 reagent, S1 reagent and S2 reagent freeze-drying form S1 dried frozen aquatic products and S2 dried frozen aquatic products; It is mixed with S1 freeze-drying redissolution reagent containing Tris-HCl sodium azide solution redissolution S1 dried frozen aquatic products; Ultrapure water dissolves S2 dried frozen aquatic products makes S2 freeze-drying redissolution reagent; Many person-portions pooled plasma carries out freeze-drying, prepares ATIII calibration object; ATIII calibration object is carried out definite value, and definite value scope ATIII% is 90%��110%; Adopting the ATIII calibration object of definite value, S1 freeze-drying to redissolve reagent and reagent production standard curve is redissolved in S2 freeze-drying, linearly dependent coefficient is greater than 0.99; Color reaction is carried out after plasma sample to be measured adds S1 freeze-drying redissolution reagent and S2 freeze-drying redissolution reagent. The test kit cost that the method prepares is low, linearity range width, and good stability is simple to operate.

Description

The preparation method of Antithrombin III determination of activity test kit
Technical field
The present invention relates to a kind of clinical detection reagent preparation method, it is specially the preparation method of Antithrombin III determination of activity test kit.
Background technology
Antithrombin III (antithrombinIII, ATIII) is the inhibitor containing the proteolytic enzyme of Serine such as zymoplasm and factor XI, plasma thromboplastin antecedent I ��, XI ��, IX ��, X ��. It is combined by arginine-Serine peptide bond with zymoplasm. Forming ATIII antithrombin complex and make enzyme-deactivating, heparin can accelerate this reaction and reach more than thousand times. Cause ATIII conformational change after Lysine binding contained by heparin and ATIII, the arginine residues contained by ATIII is more easily combined with the serine residue of zymoplasm. Once heparin-ATIII antithrombin complex is formed, heparin just dissociates from mixture, is again combined and recycled with another molecule ATIII. ATIII-antithrombin complex is then eliminated by reticuloendothelial system. Relative literature proves, in clinical upper blood plasma, the activity change of AT-III and multiple disease are closely related. Increasing or reducing of AT-III is key hemorrhage, thrombus, and it is significant in the diagnosis of the diseases such as hepatopathy, ephrosis, tuberculosis, tumour, DIC, pregnancy induced hypertension syndrome, and the assistance diagnosis aspect of the burst diseases such as cerebral infarction, heart stalk is shown important especially. Therefore, AT-III Activity determination has a good application prospect clinically.
ATIII Chromogenic assay Cleaning Principle adds excessive zymoplasm in blood plasma to be measured, in zymoplasm and blood plasma, ATIII forms 1: 1 mixture, remaining thrombin action is in chromophoric substrate, cracking goes out the group that develops the color, colour developing degree is proportionate with the amount of residue zymoplasm, and with the activity of ATIII in blood plasma in negative correlation. Apply more and more extensive in clinical studies. The existing supply of the test kit of the AT-III Chromogenic assay activity of current import, but expensive. Therefore, the AT-III Activity determination test kit researching and developing reasonable price, specificity and the higher domestic independent brand of sensitivity is significant and be worth for raising AT-III clinical diagnosis level.
Patent CN102690862A, discloses a kind of Antithrombin III and measures test kit (Chromogenic assay), owing to have employed the zymoplasm of heparin derivatives and import, and therefore cost compare height. And the prior art needs change parameter when carrying out ATIII Activity determination on full automatic blood-coagulation instrument, the parameter of change is blood plasma 5 �� l to be measured, get 50 �� l blood plasma and 60 �� lR1 reagent after adding 120 �� l diluents again, then add 60 �� lR2 reagent, finally develop the color. In the design of this external Backend parameter, it is necessary to change parameter light quantity is arranged, and the parameter light quantity value that machine self is arranged in the detection is " 200-400 ", need " 200 " change into " 0 " in the process of detection. This technology is due to cost compare height, and because this reducing the consumption of reagent, reducing of volume may cause the numerical value of last part in the process of colorimetric not show. Therefore, parameter light quantity value is arranged adjustment in order to " 0 ". This technical costs is higher, and inconvenient operation, also easily there is error in result.
Summary of the invention
For above-mentioned technical problem, the present invention provides a kind of method preparing ATIII Activity determination test kit. The product cost prepared is low, good stability, can supporting use for multiple Blood coagulation instrument, meets the clinical requirement for ATIII Activity determination.
For achieving the above object, the present invention provides following technical scheme,
The preparation method of Antithrombin III determination of activity test kit, comprises the following steps:
(1) using 10��50mmol/LTris-HCl solution of pH8.4 zymoplasm lyophilized powder and heparin sodium to be dissolved, be mixed with S1 reagent, the concentration of thrombin of S1 reagent is 5��20IU/mL, and heparin concentration is 0.2��10IU/mL;
(2) 10��50mmol/LTris-HCl of chromophoric substrate S-2238 or Sar-Pro-Arg-P-nitroanilide pH7.0 is dissolved, it is mixed with the solution that concentration of substrate is 2��5 ��m of ol/mL, be S2 reagent;
(3) in S1 reagent and S2 reagent, add auxiliary agent respectively and carry out freeze-drying, form S1 dried frozen aquatic products and S2 dried frozen aquatic products;
The content of the auxiliary agent that S1 reagent adds in S1 reagent is: BSA to be 0.5��5%, KCl concentration be 15��250mmol/L, EDTA-2K concentration are 1��10mmol/L, Trypsin inhibitor,Trasylol 0.1��5IU/mL, polyethylene glycol 6000 concentration is 1��5mg/ml;
The mass ratio of the auxiliary agent that S2 reagent adds in S2 reagent is: BSA is 0.5��5%, N.F,USP MANNITOL is 1��5%;
(4) use the S1 reagent redissolution liquid redissolution S1 dried frozen aquatic products of 10��50mmol/LTris-HCl containing pH8.4,0.1��0.5mg/ml sodiumazide, it is mixed with S1 freeze-drying redissolution reagent; Use ultrapure water to dissolve S2 dried frozen aquatic products, it is mixed with S2 freeze-drying redissolution reagent;
(5) take fresh many person-portions pooled plasma, add stablizer, sanitas material carry out freeze-drying, prepare ATIII calibration object;
Adopting WHO/BS/10.2146 standard substance, on full automatic blood-coagulation instrument CA-1500, ATIII calibration object is carried out definite value, definite value scope ATIII% is 90%��110%;
(6) on full automatic blood-coagulation instrument CA-1500, adopting the ATIII calibration object of definite value, S1 freeze-drying to redissolve reagent and reagent production standard curve is redissolved in S2 freeze-drying, linearly dependent coefficient is greater than 0.99;
(7) plasma sample to be measured is used to detect on full automatic blood-coagulation instrument CA-1500, detection obtains the OD value of plasma sample to be measured, machine calculates the activity value of ATIII in plasma sample to be measured automatically, trace routine is as follows: carrying out color reaction after adding 175 �� lS1 freeze-drying redissolution reagent and 33 �� lS2 freeze-drying redissolution reagent in 16 �� l plasma samples to be measured, whole process does not adjust any parameter of instrument self.
The present invention provides the preparation method of Antithrombin III determination of activity test kit, the test kit cost prepared is low, linearity range is wide reaches 200%��3.1%, good stability, full automatic blood-coagulation instrument detects and does not need to change any parameter, simple to operate, supporting can use for multiple Blood coagulation instrument, meet the clinical requirement for ATIII Activity determination.
Embodiment
In conjunction with the embodiments, the present invention is set forth further:
Embodiment is to prepare ATIII Activity determination reagent and is specifically detected as example on full automatic blood-coagulation instrument CA-1500.
(1) 10��50mmol/LTris-HCl, pH8.4 solution is used zymoplasm lyophilized powder and heparin sodium to be dissolved, the zymoplasm of different concns and heparin sodium aqua are mixed, being mixed with S1 reagent, concentration of thrombin is 5��20IU/mL, and heparin concentration is 0.2��10IU/mL.
(2) 10��50mmol/LTris-HCl of chromophoric substrate S-2238 or Sar-Pro-Arg-P-nitroanilide pH7.0 is dissolved, it is mixed with the solution that concentration of substrate is 2��5 ��m of ol/mL, be S2 reagent.
(3) in S1 reagent and S2 reagent, add stablizer respectively and vehicle carries out freeze-drying, S1 dried frozen aquatic products and S2 dried frozen aquatic products can be prepared into. The content of the auxiliary agent that S1 reagent adds in S1 reagent is: 0.5%��5%BSA, 20��50mmol/LTris-HCl, 15��250mmol/LKCl, 1��10mmol/LEDTA-2K, 0.1��5IU/mL Trypsin inhibitor,Trasylol, 1��5mg/ml polyethylene glycol 6000; The mass ratio of the auxiliary agent that S2 reagent adds in S2 reagent is: BSA is 0.5��5%, N.F,USP MANNITOL is 1��5%.
(4) use the S1 reagent redissolution liquid redissolution S1 dried frozen aquatic products of 10��50mmol/LTris-HCl containing pH8.4,0.1��0.5mg/ml sodiumazide, it is mixed with S1 freeze-drying redissolution reagent; Use ultrapure water to dissolve S2 dried frozen aquatic products, it is mixed with S2 freeze-drying redissolution reagent.
(5) on CA-1500, it may also be useful to the ATIII calibration object production standard curve that definite value is good, the typical curve linearly dependent coefficient of making is greater than 0.99.
(6) plasma sample to be measured is used to detect on full automatic blood-coagulation instrument CA-1500, detection obtains the OD value of sample, machine calculates the activity value of ATIII in sample to be tested automatically, trace routine is as follows: carrying out color reaction after adding 175 �� lS1 freeze-drying redissolution reagent and 33 �� lS2 freeze-drying redissolution reagent in 16 �� l blood plasma, whole process does not adjust any parameter of instrument self.
Test of product performance is tested:
(1) detected result on full automatic blood-coagulation instrument
With SysmexCA-1500 Automatic coagulometer and supporting Antithrombin III detection reagent (SIEMENS) and the present embodiment ATIII detection reagent production standard curve, the results are shown in Table 1.
Table 1ATIII standard curve making result
ATIII (%) Embodiment reagent SIEMENS reagent
150 0.407 0.407
100 0.713 0.750
50 1.154 1.154
25 1.360 1.272
12.5 1.452 1.390
R2 -0.998 -0.998
As seen from the above table, the typical curve that the present embodiment products obtained therefrom makes is good R linearly2> 0.99, detected result is consistent with import SIEMENS company product.
(2) product redissolution Detection of Stability
ATIII embodiment prepared is divided into 3 parts after redissolving, and is placed in 37 DEG C, 2 DEG C-8 DEG C and room temperature (20 DEG C-25 DEG C) preservation respectively, and sampling at regular intervals carries out typical curve preparation, and result is such as table 2 and table 3:
Table 2SIEMENS company reagent redissolves rear 37 DEG C of study on the stability results
ATIII (%) Before placement 2 hours 4 hours 6 hours 8 hours 24 hours
150 0.483 0.507 0.450 0.462 0.442 0.053
100 0.804 0.789 0.759 0.739 0.752 0.321
50 1.098 1.117 1.059 1.067 1.081 0.629
25 1.270 1.232 1.266 1.241 1.251 0.806
12.5 1.322 1.304 1.456 1.305 1.279 0.898
R2 -1.000 -0.999 -0.999 -0.998 -0.997 -0.998
The reagent rear 37 DEG C of study on the stability results of redissolution that table 3 embodiment is obtained
By the data of table 2 and table 3 it will be seen that the equal < 10% of fluctuation range of self-control reagent detected result in 8 hours of 37 DEG C of insulations, linearly dependent coefficient >=0.99. 37 DEG C of insulations are after 24 hours, the numerical value of self-control reagent and SIEMENS reagent all has reduction, but compare import SIEMENS reagent, it is obvious that SIEMENS reagent is placed in the reduction of the numerical value after 37 DEG C, therefore makes reagent by oneself at 37 DEG C of good stabilities being incubated 24 hours in import SIEMENS reagent.
Reagent rear 2 DEG C-8 DEG C study on the stability results of redissolution that table 4 embodiment is obtained
ATIII (%) Before placement 2 hours 4 hours 8 hours 48 hours 96 hours
150 0.540 0.537 0.502 0.516 0.486 0.503
100 0.782 0.733 0.723 0.787 0.752 0.788
50 1.084 1.165 1.038 1.077 1.024 1.091
25 1.241 1.304 1.219 1.145 1.184 1.242
12.5 1.288 1.350 1.286 1.230 1.265 1.333
R2 -0.999 -0.998 -0.996 -0.998 -0.998 -1.000
Table 4 places each detection in front and back numerical fluctuations range L EssT.LTssT.LT 10% at 2 DEG C��8 DEG C, linearly dependent coefficient >=0.99 after proving embodiment redissolution, it is possible to think that latter 2 DEG C��8 DEG C of self-control reagent redissolution prepared by the present invention has good stability.
After the reagent redissolution that table 5 embodiment is obtained, room temperature stability investigates result
ATIII (%) Before placement 2 hours 4 hours 8 hours 48 hours 96 hours
150 0.540 0.563 0.537 0.528 0.532 0.562
100 0.782 0.784 0.774 0.788 0.753 0.797
50 1.084 1.085 1.089 1.092 1.038 1.092
25 1.241 1.250 1.253 1.248 1.219 1.234
12.5 1.288 1.306 1.312 1.303 1.286 1.296
R2 -0.997 -0.998 -0.996 -0.998 -0.996 -0.999
Table 5 experimental result proves that ATIII Activity determination reagent stability prepared by the present invention is better, the equal < 10% of the fluctuation range of detected result, linearly dependent coefficient >=0.99, it is possible to think that the rear room temperature of this product redissolution is deposited and can keep stable in 96 hours.
(3) freeze-drying prods Detection of Stability
ATIII freeze-dried reagent embodiment prepared, is placed in 37 DEG C respectively, and room temperature (20 DEG C-25 DEG C) preserves, and sampling at regular intervals carries out standard curve determination preparation, and to investigate reagent stability, result is as follows:
Table 6 freeze-drying prods 37 DEG C of study on the stability results
ATIII (%) Before placement 1 day 2 days 3 days 4 days 7 days
150 0.477 0.435 0.423 0.489 0.410 0.452
100 0.742 0.713 0.702 0.728 0.712 0.707
50 1.037 0.994 0.956 0.993 0.937 0.967
25 1.175 1.135 1.109 1.139 1.091 1.115
12.5 1.248 1.219 1.168 1.219 1.150 1.204
R2 -1.000 -0.999 -0.999 -0.999 -0.996 -0.999
Table 6 result display self-control reagent dried frozen aquatic products is at the equal < 10% of fluctuation range of 37 DEG C of insulation detected results after 7 days, and the good > 0.99 of linear preservers, show that self-control freeze-drying prods is incubated 7 days rear stabilities at 37 DEG C good.
Table 7 freeze-drying prods room temperature stability investigates result
ATIII (%) Before placement 1 day 2 days 3 days 4 days 7 days
150 0.477 0.505 0.486 0.462 0.477 0.484
100 0.742 0.783 0.742 0.745 0.740 0.722
50 1.037 1.051 1.022 1.015 1.001 1.012
25 1.175 1.215 1.149 1.170 1.153 1.162
12.5 1.248 1.265 1.233 1.243 1.213 1.232
R2 -1.000 -0.999 -1.000 -0.999 -1.000 -0.999
Table 7 result display self-control reagent dried frozen aquatic products is at the equal < 10% of fluctuation range of incubation at room temperature detected result after 7 days, and linearly dependent coefficient >=0.99, shows that self-control freeze-drying prods is good at incubation at room temperature 7 days rear stabilities.

Claims (1)

1. the preparation method of Antithrombin III determination of activity test kit, it is characterised in that, comprise the following steps:
(1) using 10��50mmol/LTris-HCl solution of pH8.4 zymoplasm lyophilized powder and heparin sodium to be dissolved, be mixed with S1 reagent, the concentration of thrombin of S1 reagent is 5��20IU/mL, and heparin concentration is 0.2��10IU/mL;
(2) 10��50mmol/LTris-HCl of chromophoric substrate S-2238 or Sar-Pro-Arg-P-nitroanilide pH7.0 is dissolved, it is mixed with the solution that concentration of substrate is 2��5 ��m of ol/mL, be S2 reagent;
(3) in S1 reagent and S2 reagent, add auxiliary agent respectively and carry out freeze-drying, form S1 dried frozen aquatic products and S2 dried frozen aquatic products;
The content of the auxiliary agent that S1 reagent adds in S1 reagent is: BSA to be 0.5��5%, KCl concentration be 15��250mmol/L, EDTA-2K concentration are 1��10mmol/L, Trypsin inhibitor,Trasylol 0.1��5IU/mL, polyethylene glycol 6000 concentration is 1��5mg/ml; The mass ratio of the auxiliary agent that S2 reagent adds in S2 reagent is: BSA is 0.5��5%, N.F,USP MANNITOL is 1��5%;
(4) use the S1 reagent redissolution liquid redissolution S1 dried frozen aquatic products of 10��50mmol/LTris-HCl containing pH8.4,0.1��0.5mg/ml sodiumazide, it is mixed with S1 freeze-drying redissolution reagent; Use ultrapure water to dissolve S2 dried frozen aquatic products, it is mixed with S2 freeze-drying redissolution reagent;
(5) take fresh many person-portions pooled plasma, add stablizer, sanitas material carry out freeze-drying, prepare ATIII calibration object;
Adopting WHO/BS/10.2146 standard substance, on full automatic blood-coagulation instrument CA-1500, ATIII calibration object is carried out definite value, definite value scope ATIII% is 90%��110%;
(6) on full automatic blood-coagulation instrument CA-1500, adopting the ATIII calibration object of definite value, S1 freeze-drying to redissolve reagent and reagent production standard curve is redissolved in S2 freeze-drying, linearly dependent coefficient is greater than 0.99;
(7) plasma sample to be measured is used to detect on full automatic blood-coagulation instrument CA-1500, detection obtains the OD value of plasma sample to be measured, machine calculates the activity value of ATIII in plasma sample to be measured automatically, trace routine is as follows: carrying out color reaction after adding 175 �� lS1 freeze-drying redissolution reagent and 33 �� lS2 freeze-drying redissolution reagent in 16 �� l plasma samples to be measured, whole process does not adjust any parameter of instrument self.
CN201510151571.XA 2015-04-01 2015-04-01 The preparation method of Antithrombin III determination of activity test kit Expired - Fee Related CN104714036B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510151571.XA CN104714036B (en) 2015-04-01 2015-04-01 The preparation method of Antithrombin III determination of activity test kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510151571.XA CN104714036B (en) 2015-04-01 2015-04-01 The preparation method of Antithrombin III determination of activity test kit

Publications (2)

Publication Number Publication Date
CN104714036A CN104714036A (en) 2015-06-17
CN104714036B true CN104714036B (en) 2016-06-01

Family

ID=53413544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510151571.XA Expired - Fee Related CN104714036B (en) 2015-04-01 2015-04-01 The preparation method of Antithrombin III determination of activity test kit

Country Status (1)

Country Link
CN (1) CN104714036B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106568765B (en) * 2015-10-12 2020-08-04 上海长岛生物技术有限公司 Thrombin chromogenic substrate solution for determining antithrombin III activity, thrombin aqueous solution, method and kit
CN105466920A (en) * 2015-11-20 2016-04-06 鲁翌 A rapid antithrombin III detecting kit based on interaction between thrombin and a chromogenic substrate and a detecting method thereof
CN106153612A (en) * 2015-12-04 2016-11-23 上海贞元诊断用品科技有限公司 Antithrombin activity detectable and its preparation method and application
CN106893759A (en) * 2015-12-21 2017-06-27 徐淼 A kind of adenosine deaminase detection reagent
CN107167439A (en) * 2017-06-30 2017-09-15 上海贞元诊断用品科技有限公司 A kind of kit that dabigatran content is detected based on Chromogenic assay
CN107255622A (en) * 2017-06-30 2017-10-17 上海贞元诊断用品科技有限公司 A kind of kit that dabigatran content is detected based on fibrin ferment Chromogenic assay
CN111826418A (en) * 2020-08-28 2020-10-27 保定天岳生物工程有限公司 Antithrombin III determination kit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918718A1 (en) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Methods and devices for electrochemical determination of factor Xa inhibitors in blood samples
FR2934052B1 (en) * 2008-07-17 2011-11-25 Stago Diagnostica ASSAY OF THE ACTIVITY OF CIRCULATING TISSUE FACTOR
CN102690862B (en) * 2012-06-08 2015-01-28 上海太阳生物技术有限公司 Kit (Developing substrate method) for testing antithrombase III (AT-III)
CN104166004B (en) * 2014-09-04 2016-01-13 中国医学科学院输血研究所 Platelet cofactor Ⅰ quality-control product preparation method

Also Published As

Publication number Publication date
CN104714036A (en) 2015-06-17

Similar Documents

Publication Publication Date Title
CN104714036B (en) The preparation method of Antithrombin III determination of activity test kit
Coutinho et al. New biomarkers in endometriosis
CN102690862B (en) Kit (Developing substrate method) for testing antithrombase III (AT-III)
US20230357762A1 (en) Euglobulin-based method for determining the biological activity of defibrotide
CN109239061A (en) A kind of liquid-type Antiprothrombin antibodies assay kit
Lyons et al. Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions
CN100365409C (en) Reagent for measuring low-density lipoproteincholesterol and preparation method
JP2021164678A (en) Evacuated blood collection tubes containing protease inhibitors for assessment of contact system activation
Sun et al. Establishment of a sandwich ELISA using commercial antibody for plasma or serum 3-nitrotyrosine (3NT). Elevation in inflammatory diseases and complementary between 3NT and myeloperoxidase
Kaczor et al. The prevalence of alpha1-antitrypsin deficiency in a representative population sample from Poland
Evans et al. Prevalence of alpha 1-antitrypsin Pi types among newborn infants of different ethnic backgrounds
CN112662735B (en) Antithrombin III activity determination kit and preparation method thereof
CN107576799A (en) A kind of razaxaban reagent box for detecting content and its method for detecting razaxaban
CN108982885B (en) Kit for measuring alpha-amylase in serum
Ipcioglu et al. Prolidase activity in serum and pleural fluids in patients with tuberculous pleural effussion
Zhang et al. Determination of Thrombin Activity by Reversed-phase High Performance Liquid Chromatography
RU2766143C2 (en) Liquid defibrotide composition for treatment and prevention of venous occlusive disease
CN108398390A (en) A kind of active method of measurement serpin
CN102384893A (en) Seminal plasma gamma-L-glutamyl transpeptidase activity quantitative detecting reagent kit and application thereof
Kramer et al. Assay of trypsin activity of human serum with a chromogenic substrate, CBZ-diglycyl-l-arginyl-2-naphthylamide hydrochloride (GGANA)
CN114034655A (en) Method for detecting activity of defibrase raw material and preparation thereof and application
CN1920564B (en) Application of cell transcription factor ILF-1
CN106093017A (en) A kind of test kit measuring Ischemia modified albumin IMA and preparation method thereof
CN115219486A (en) Detection kit for anti-Xa activity of heparin and low molecular heparin and non-disease diagnosis detection method thereof
CN117434281A (en) Composition, detection reagent, detection kit and application thereof in preparation of blood coagulation factor X activity detection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160601

Termination date: 20210401

CF01 Termination of patent right due to non-payment of annual fee